Birdie, Nomad Health, Pepscan
London-based Birdie raises €28.4 million to support more personalised home care for the elderly
Leading home-health platform Birdie has just secured an additional €24.8 million in its mission to reinvent home health care through tech, with Sofina leading the round alongside OMERS Ventures and follow-on investment coming from Index Ventures.
Birdie aims to empower more personalised care for the elderly in the comfort of their own homes. The funding will push forward this vision.
Founded in 2017, Birdie operates on the ethos that the elder generation should have vibrant and happy lives as they age in the comfort of their own home. Not only is this undoubtedly better for their mental health, but it also decreases the strain on families and an already frazzled hospital care system. The healthtech solution comprises an all-in-one platform that supports millions of care visits every month. It equips care providers with the tools they need to deliver better quality care and improve efficiency across most day-to-day operations. From scheduling visits, creating care plans, preparing audit reports and invoicing to full-service care management, the platform enables professionals to deliver care safely and efficiently. It further decreases the time spent on non-critical admin and relieves stressed-out workers of labour some paperwork.
London-based Birdie raises €28.4 million to support more personalised home care for the elderly | EU-Startups
Leading home-health platform Birdie aims to empower more personalised care for the elderly in the comfort of their own homes. The startup has just raised
H2SITE Raises €12.5M in Series A Funding
H2SITE, a Bilbao, Spain-based deep-tech pioneer in on-site hydrogen (H2) production, raised 12,5M€ in Series A funding.
The round was led by Breakthrough Energy Ventures (BEV), with participation from Equinor Ventures, ENGIE New Ventures, TECNALIA, Capital Riesgo País Vasco and Seed Capital Bizkaia.
Led by Andrés Galnares, CEO, H2SITE is a deep-tech start-up that uses advanced membrane reactor technology to solve the hydrogen transport problem by converting hydrogen carriers with supply chains and separating hydrogen gas blends into fuel cell purity hydrogen.
The funding will accelerate the scale up of the company’s integrated membrane reactor and membrane separation technologies to obtain fuel cell purity hydrogen from ammonia or methanol cracking, or enable hydrogen transportation in existing natural gas infrastructure. H2SITE will also increase its membrane manufacturing capabilities, operating a world unique membrane manufacturing plant in the North of Spain.
H2SITE Raises €12.5M in Series A Funding
H2SITE, a Bilbao, Spain-based deep-tech pioneer in on-site hydrogen (H2) production, raised 12,5M€ in Series A funding
Nomad Health Raises $105M in Funding
Nomad Health, a NYC-based digital marketplace for temporary healthcare jobs, raised $105m in financing.
The round, which brought total funding to over $200 million since its founding in 2015, was co-led by Adams Street Partners and Icon Ventures with participation from new equity investor HealthQuest Capital and existing investors Polaris Partners, .406 Ventures, AlleyCorp, and RRE Ventures, and new debt providers J.P. Morgan and Trinity Capital. In conjunction with the funding, Garheng Kong, MD, PhD, MBA, the founder and managing partner of HealthQuest Capital, will join Nomad Health’s Board of Directors.
The company intends to use the funds to expand its marketplace beyond travel nurses to now serve an expansive group of allied health professionals, including laboratory technicians, physical therapists, and ultrasound technicians.
Led by CEO and co-founder Alexi Gharib Nazem, M.D., M.B.A., Nomad Health has built an online marketplace for temporary clinical jobs. The user base now includes more than 250,000 healthcare workers who have submitted nearly half a million job applications on the platform.
Nomad Health Raises $105M in Funding - FinSMEs
Nomad Health, a NYC-based digital marketplace for temporary healthcare jobs, raised $105m in financing
Tomorrow Health Raises $60M in Series B Funding
Tomorrow Health, a New York-based home-based care company, raised $60M in Series B funding.
The round was led by Bond, with participation from Andreessen Horowitz, Obvious Ventures, BoxGroup, and Sound Ventures.
The company intends to use the funds to accelerate its expanding partnerships with national and regional health plans, growth in new markets, and investment in its technology.
Led by CEO Vijay Kedar, Tomorrow Health enables healthcare for patients and their families at home. The company streamlines the home-based care process to elevate the patient experience via a data-driven marketplace that matches patients and their families with home-based care suppliers, simplifies ordering and insurance processes, and offers support at every step.
Tomorrow Health Raises $60M in Series B Funding - FinSMEs
Tomorrow Health, a New York-based home-based care company, raised $60M in Series B funding
Swiss-based Biosynth Carbosynth acquires Dutch company Pepscan
Switzerland-based Biosynth Carbosynth, a supplier of hybrid research products and services to the life sciences industry, announced on Thursday (June 30, 2022) that it has acquired Pepscan, a Dutch company that provides peptide-based products and services.
Biosynth’s ability to deliver chemical manufacturing services “from the first idea to the finished product” is now matched in peptides, with Pepscan’s expertise in both lead discovery & optimisation and GMP production, combining with the capabilities of Vivitide, the US peptide specialists, which joined Biosynth in March.
With this acquisition, the two businesses will combine to create Biosynth’s new Peptide division, which will serve the academic community as well as the pharmaceutical and biotechnology, diagnostics and cosmetics sectors.
Founded in 1999, Pepscan claims to deliver customer-centric peptide products and services by integrating smart science with manufacturing capabilities. Peptides are short chains of amino acids linked by peptide bonds. Peptide therapeutics are used for the treatment of diseases. Naturally occurring peptides may serve as hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infectives – peptide therapeutics mimic such functions.
With its peptide-based epitope mapping service platform, Pepscan also supports biotech companies in developing their antibody pipelines. The underlying protein mimicry platform delivers binding insights, even in cases where other technologies fall short.
Swiss-based Biosynth Carbosynth acquires Dutch company Pepscan: Know more | Silicon Canals
Pepscan claims to deliver customer-centric peptide products and services by integrating smart science with manufacturing capabilities.
Arch Venture Partners Closes Fund XII, at $2.975 Billion
Arch Venture Partners, a Chicago, IL-based venture capital firm, closed Arch Venture Fund XII, at $2.975 billion.
The fund will invest in the creation, development and funding of early stage biotechnology companies with potential to solve some of the biggest health challenges in areas including infectious disease, mental health, immunology, oncology, neurology, age-related diseases, manufacturing, clinical trials, genomic and biological tools, data sciences, and ways to reimagine diagnostics and therapies.
Arch Venture Partners Closes Fund XII, at $2.975 Billion
Arch Venture Partners, a Chicago, IL-based venture capital firm, closed Arch Venture Fund XII, at $2.975 billion
Telegraph Hill Partners Raises $525M Fifth Fund
Telegraph Hill Partners, a San Francisco, CA-based venture capital and growth equity firm dedicated to building life science and healthcare technology businesses, closed THP V, at $525m.
The fund will make investments in innovative companies that are commercializing advanced technologies in areas including life science tools, reagents, specialty chemistries, medical technology, medical devices, diagnostics, healthcare IT, healthcare services, agriculture and animal health.
Consistent with its previous funds, THP V will invest in innovative companies across the lifecycle from startup to fully scaled. Investments will be structured to effectively address the capital needs of each company and its founders, and will include startup and growth capital, existing shareholder liquidity events, acquisitions/buyouts and corporate divestitures.
